Technical Analysis for LQDA - Liquidia Technologies, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Earnings Movers | Other | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.46% | |
Earnings Movers | Other | -1.46% | |
Wide Bands | Range Expansion | -2.89% | |
Wide Bands | Range Expansion | -0.47% | |
Oversold Stochastic | Weakness | -0.47% | |
180 Bearish Setup | Bearish Swing Setup | 2.61% | |
Wide Bands | Range Expansion | 2.61% | |
Oversold Stochastic | Weakness | 2.61% | |
Bullish Engulfing | Bullish | 2.08% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | 3 days ago |
Fell Below 10 DMA | 3 days ago |
10 DMA Support | 3 days ago |
Down 2 % | 3 days ago |
Non-ADX 1,2,3,4 Bearish Retracement Entry | 3 days ago |
Get a Trading Assistant
- Earnings date: 05/02/2024
Liquidia Technologies, Inc. Description
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pain Medication Hypertension Clinical Trial Opioids Pulmonary Arterial Hypertension Uniform Bupivacaine Inhaler Treprostinil
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.99 |
52 Week Low | 5.71 |
Average Volume | 842,665 |
200-Day Moving Average | 10.04 |
50-Day Moving Average | 14.36 |
20-Day Moving Average | 13.51 |
10-Day Moving Average | 12.78 |
Average True Range | 0.68 |
RSI (14) | 39.02 |
ADX | 20.57 |
+DI | 17.27 |
-DI | 26.02 |
Chandelier Exit (Long, 3 ATRs) | 13.85 |
Chandelier Exit (Short, 3 ATRs) | 13.85 |
Upper Bollinger Bands | 15.32 |
Lower Bollinger Band | 11.71 |
Percent B (%b) | 0.3 |
BandWidth | 26.74 |
MACD Line | -0.53 |
MACD Signal Line | -0.51 |
MACD Histogram | -0.0233 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.65 | ||||
Resistance 3 (R3) | 13.70 | 13.46 | 13.50 | ||
Resistance 2 (R2) | 13.46 | 13.25 | 13.44 | 13.45 | |
Resistance 1 (R1) | 13.13 | 13.11 | 13.01 | 13.08 | 13.41 |
Pivot Point | 12.89 | 12.89 | 12.84 | 12.87 | 12.89 |
Support 1 (S1) | 12.56 | 12.68 | 12.44 | 12.51 | 12.17 |
Support 2 (S2) | 12.32 | 12.54 | 12.30 | 12.13 | |
Support 3 (S3) | 11.99 | 12.32 | 12.08 | ||
Support 4 (S4) | 11.94 |